28 November 2020
25 November 2020
21 November 2020
This editorial sheds light on the necessity to develop and implement an effective vaccine, stresses the financial interests of the companies developing the vaccines, and underlines the great challenges posed by the unknown of a still young pandemic.
20 November 2020
This opinion, written by Charlie Weller, explores why is it important to keep working on and investing in the hundreds of Covid-19 vaccines still in development.
19 November 2020
This ECDC document is intended to facilitate further discussions between Member States with the aim of reaching agreement on the criteria to be used for the selection of rapid antigen tests, as well as scenarios and settings during which it is appropriate to use rapid antigen tests. This document is also intended to support clinical validations of rapid antigen tests.
18 November 2020
The European Commission adopted a recommendation on the use of rapid antigen tests for the diagnosis of COVID-19.
The recommendation provides guidance on how to select rapid antigen tests, when they are appropriate and who should perform them. It also calls for validation and mutual recognition of tests and their results.
This document aims to help public health authorities in EU/EEA countries and the UK in their tracing and management of persons, including healthcare workers, who have had contact with COVID-19 cases.
14 November 2020
This review discusses what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.
13 November 2020
The Commission has signed a grant of 1 M€ to support the conduct of a clinical trial using Raloxifene for patients suffering from COVID-19.
This grant has been signed under the Emergency Support Instrument (ESI), which provides EU funding to support the generation of clinical evidence that would support an application for a new marketing authorisation. This would repurpose an existing medicinal product to treat COVID-19 patients.
President Ursula von der Leyen welcomed Member States' COVID-19 scientific advisors to the first meeting of the EU scientific advice platform on COVID-19. The platform will facilitate more co-ordinated scientific advice on the approach to Member State COVID-19 public health measures across the EU. It complements the President's COVID-19 advisory panel and the work of the European Centre for Disease Prevention and Control (ECDC).
12 November 2020
This document contains summary information on the latest projections from the IHME model on COVID-19 in the European Region. The model was run on November 11, 2020.
In a nutshell: in aggregate, exponential growth in cases and deaths continues in the region, mask use and reductions in mobility are helping in slowing the transmission, but countries could benefit from more aggressive action.
New WHO interim guidance provides useful information on what Member States, health-care authorities and employers can do to protect migrant workers from COVID-19 and its repercussions. It further highlights the essential contribution of migrant workers to their host societies in the WHO European Region, and how COVID-19 preparedness, response and recovery activities are impacting migrant workers’ health.
10 November 2020
WHO/Europe has just launched its Public Health and Social Measures (PHSM) Severity Index to provide standardized data on the ways in which countries in the WHO European Region have sought to slow or stop community spread of COVID-19. This latest tool systematically captures and analyses individual governmental PHSM responses to COVID-19 in the 53 countries of the Region.
The European Center for Disease Prevention and Control has released a Q&A page on COVId-19. You can learn more about the basic facts, but also about prevention, medical information and the situation in the EU.
5 November 2020
The Commission is supporting 23 new research projects with a total of €128 million to address the continuing coronavirus pandemic and its effects.
The 23 projects involve 344 research teams from 39 countries, including 32 participants from 15 countries outside of the EU. The funding will enable researchers to strengthen and adapt industrial capacity to manufacture and deploy equipment such as ventilators, to prevent and treat coronavirus, to develop medical technologies and digital tools such as portable diagnostic system, to better understand the societal impacts of the pandemic, for example on vulnerable and marginalised groups, and to learn from large groups of patients (cohorts) across Europe in order to improve treatment.
The funding under Horizon 2020, the EU’s research and innovation programme, is part of the Commission's €1.4 billion pledge to the Coronavirus Global Response initiative, launched by President Ursula von der Leyen in May 2020.
Trends in reported cases and testing
- By the end of week 44 (1 November 2020), the 14-day case notification rate for the EU/EEA and the UK, based on data collected by ECDC from official national sources from 31 countries, was 496.0 (country range: 51.1–1785.6) per 100 000 population. The rate has been increasing for 105 days.
- High levels (at least 60 per 100 000) or sustained increases (for at least seven days) in the 14-day COVID-19 case notification rates compared with the previous week have been observed in 30 countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK).
- Based on data reported to TESSy from 24 countries, among people over 65 years of age, high levels (at least 60 per 100 000) or sustained increases in the 14-day COVID-19 case notification rates compared to last week have been observed in 23 countries (Austria, Belgium, Croatia, Cyprus, Czechia, Denmark, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain and Sweden).
- Notification rates are highly dependent on several factors, one of which is the testing rate. Weekly testing rates for week 44, available for 29 countries, varied from 891 to 12 479 tests per 100 000 population. Luxembourg had the highest testing rate for week 44, followed by Denmark, Malta, Belgium and Iceland.
- Weekly test positivity was high (at least 3%) or had increased against the previous week in 25 countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Portugal, Romania, Slovenia, Spain, Sweden and the UK).
- In the five countries that reported data from primary care sentinel surveillance for COVID-19 up to week 44, using the systems established for influenza, nine detections of SARS-CoV-2 were reported among the 70 patients tested.
Hospitalisation and ICU
- Pooled data from 16 countries for week 44 show that there were 1.7 patients per 100 000 population in ICU due to COVID-19, which is 66% of the peak ICU occupancy observed during the pandemic. Pooled weekly ICU admissions based on data from 10 countries were 2.1 new admissions per 100 000, which is 54% of the peak rate to date.
- Hospital and/or ICU occupancy and/or new admissions due to COVID-19 were high (at least 25% of the peak level during the pandemic) or had increased compared to the previous week in 28 countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden and the UK). No other increases have been observed, although data availability varies.
- Based on surveillance data reported to TESSy by 24 countries to date, we estimate that 15% (country range: 2–78%) of reported COVID-19 cases have been hospitalised. Data from 16 countries show that in total 8% (country range: 0–60%) of hospitalised patients required ICU and/or respiratory support. However, these proportions vary considerably by age and sex and may be influenced by national policies and practices.
- The 14-day COVID-19 death rate for the EU/EEA and the UK, based on data collected by ECDC from official national sources from 31 countries, was 40.2 (country range: 0.8–178.3) per million population. The rate has been increasing for 51 days.
- High levels (at least 10 per million) or sustained increases (for at least seven days) in the 14-day COVID-19 death rates compared to those reported seven days ago are currently being observed in 26 countries (Austria, Belgium, Bulgaria, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK).
Experience of emergency use authorisations for investigational Ebola virus vaccines in Guinea and the Democratic Republic of the Congo (DRC) can elucidate key lessons that can guide ethical emergency use authorisations for COVID-19 vaccines.
The evidence for the health benefits of democracy is well established, but democracies are being eroded or “autocratised.” Presidents and ruling cabals use democracy to gain power and then abuse democracy to retain it. A new study finds that this autocratisation is bad for health.1 It might partly explain why many democracies are responding poorly to the coronavirus pandemic.
3 November 2020
As countries across the WHO European Region face a steep surge in COVID-19 transmission, the latest issue of Eurohealth, released today, considers whether there is still an opportunity to use the crisis to tackle underlying problems besetting our health systems.
This special edition is a collaboration between the European Observatory on Health Systems and Policies, WHO/Europe and the European Commission, and draws on data from the COVID-19 Health System Response Monitor launched in April.
30 October 2020
This document provides interim guidance on the prevention, identification and management of health worker infection in the context of COVID-19. It is intended for occupational health departments, infection prevention and control departments or focal points, health facility administrators and public health authorities at both the national and facility level.
28 October 2020
European Commission | Press release
This day [28 October] the European Commission is launching an additional set of actions to help limit the spread of the coronavirus, save lives and strengthen the internal market's resilience. Concretely, the measures aim to better understand the virus' spread and the effectiveness of the response, ramp up well-targeted testing, bolster contact tracing, improve preparations for vaccination campaigns, and maintain access to essential supplies such as vaccination equipment, while keeping all goods moving in the single market and facilitating safe travel.
8 October 2020
Nine months into the COVID-19 pandemic, a consensus is building that without safe and effective vaccines, the COVID-19 pandemic cannot be overcome. At the same time, there is much discussion about vaccines, effectiveness, availability and such. In order to provide some clarity, EUPHA and the EUPHA Infectious diseases control section (EUPHA-IDC) set up this statement on prerequisites for a good COVID-19 vaccine programme.
Authors: Anna Odone, Sandro Galea, David Stuckler, Carlo Signorelli, the University Vita-Salute San Raffaele COVID-19 literature monitoring working group
"This surge of publications that has emerged during the current pandemic suggests that it is important to take a step back and ask two key questions. First, are we publishing what we should be publishing? Second, are we publishing the way we should be publishing?
Authors: David Patterson, Dineke Zeegers Paget
The authors of this article argue that public health should not be designed at the expense of human rights, especially during a pandemic, and offer an approach focus on State obligations to protect and promote the right to health, including in the COVID-19 crisis, firmly grounded in international law.
Trends in reported cases and testing
- By the end of week 43 (25 October 2020), the 14-day case notification rate for the EU/EEA and the UK, based on data collected by ECDC from official national sources from 31 countries, was 360.2 (country range: 37.7–1453.2) per 100 000 population. The rate has been increasing for 98 days.
- High levels (at least 60 per 100 000) or sustained increases (for at least seven days) in the 14-day COVID-19 case notification rates compared with the previous week have been observed in 28 countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK).
- Based on data reported to TESSy from 25 countries, among people over 65 years of age, high levels (at least 60 per 100 000) or sustained increases in the 14-day COVID-19 case notification rates compared to last week have been observed in 22 countries (Austria, Belgium, Croatia, Cyprus, Czechia, Denmark, Greece, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden).
- Notification rates are highly dependent on several factors, one of which is the testing rate. Weekly testing rates for week 43, available for 25 countries, varied from 746 to 9 871 tests per 100 000 population. Luxembourg had the highest testing rate for week 43, followed by Denmark, Malta, Belgium and the UK.
- Weekly test positivity was high (at least 3%) or had increased against the previous week in 22 countries (Belgium, Bulgaria, Croatia, Czechia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovenia, Spain, Sweden and the UK).
- In the seven countries that reported data from primary care sentinel surveillance for COVID-19 up to week 43, using the systems established for influenza, three detections of SARS-CoV-2 were reported among the 83 patients tested.
- Hospital and/or ICU occupancy and/or new admissions due to COVID-19 were high (at least 25% of the peak level during the pandemic) or had increased compared to the previous week in 24 countries (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Luxembourg, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia and the UK). No other increases have been observed, although data availability varies.
- Based on surveillance data reported to TESSy by 24 countries to date, we estimate that 17% (country range: 2–76%) of reported COVID-19 cases have been hospitalised. Data from 17 countries show that in total 8% (country range: 0–60%) of hospitalised patients required ICU and/or respiratory support. However, these proportions vary considerably by age and sex and may be influenced by national policies and practices.
- The 14-day COVID-19 death rate for the EU/EEA and the UK, based on data collected by ECDC from official national sources from 31 countries, was 25.7 (country range: 0.0–101.6) per million population. The rate has been increasing for 44 days.
- High levels (at least 10 per million) or sustained increases (for at least seven days) in the 14-day COVID-19 death rates compared to those reported seven days ago are currently being observed in 22 countries (Austria, Belgium, Bulgaria, Croatia, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and the UK).
7 October 2020
On 5 November 2020, health authorities in Denmark reported 12 human cases of COVID-19 caused by a specific mink-associated variant strain of the SARS-CoV-2 virus.
Denmark has assessed that the ongoing circulation of SARS-CoV-2 in mink farms, the susceptibility of the mink, and the ease of transmission at the human-animal interface represents a risk to public health in the country.
WHO/Europe convened a meeting with Danish authorities and the European Centre for Disease Prevention and Control (ECDC) on 5 November to understand and discuss the details of the findings, and offer support.
5 October 2020
Building on their policy brief “Protect, prepare, and transform Europe: Recovery and resilience post COVID-19”, the Open session emphasized the notion of creating greater resilience “by design”, not “by disaster”, at the core of a coordinated EU recovery response to the COVID-19 outbreak. ESIR experts discussed how an integrated “people, planet and prosperity” recovery model and concentrated investment in R&I-led transformation would enable us to emerge from COVID-19 with more resilient economies and societies.
26 September 2020
Author: Richard Horton
In this article, Richard Horton argues that COVID-19 should be named a syndemic, and not a pandemic. A syndemic is "characterized by social and biological interactions between conditions and states, interactions that increase a person's susceptibility to harm or worsen their health outcomes". Changing the way we name COVID-19 would broaden our vision of the disease, one that would include education, employment, housing, food, and environment, to better prevent and treat.
3 August 2020
Commission concludes talks to secure future coronavirus vaccine for Europeans
The European Commission concluded exploratory talks with a pharmaceutical company, Sanofi, to purchase a potential vaccine against COVID-19. The envisaged contract would provide for an option to purchase 300 million doses of the vaccine, on behalf of all EU Member States. Read more.
Coronavirus: Commission strengthens preparedness for future outbreaks
On 15 July, the Commission presented immediate short-term measures to strengthen EU health preparedness for COVID-19 outbreaks. In the current context where new outbreaks spread across the EU, the Communication insists on all necessary actions needed to enhance preparedness, including testing and contact tracing, improved public health surveillance and widened access to medical countermeasures. Read more.
European Commission authorises first treatment against COVID-19
On 29 July, the European Commission signed a contract with the pharmaceutical company Gilead to secure treatment doses of Veklury, the brand name for Remdesivir, which was the first medicine authorised at EU level for treatment of COVID-19. As from August, the medicine will be made available to Member States and the UK. Read more.
Commission strengthens support for treatment through convalescent plasma
The European Commission invited more than 200 blood-collection services around the EU to apply for funding for the purchase of plasmapheresis equipment which takes plasma from donors. The aim of this action, part of the Emergency Support Instrument (ESI), is to support the treatment of new COVID-19 patients by increasing EU capacity to collect convalescent plasma recovered from COVID-19 patients. Read more.
New EU framework to prepare and manage health threats discussed with Health Ministers
On 16 July Commissioner Kyriakides joined EU Health ministers at a videoconference to discuss topics such as the European Health Data Space and the supply of medicinal products in the EU. The Commissioner also stressed that the COVID-19 crisis showed the need for a stronger role for the ECDC and potentially for a new framework on cross-border threats: “We need a new framework at EU level to prepare and manage health threats. We need a stronger mandate to coordinate. This could involve new legislation or a revision of the current Decision on cross-border threats to health”. Read more.
Coronavirus: mobile tracing and warning apps one step closer
The European Commission adopted an Implementing Decision this month to support the establishment of a voluntary gateway service that facilitates the interoperability of contact tracing and warning apps. This decision will mean that citizens, in particular those traveling in the EU, will only need to install one app. Read more.
30 July 2020
Connecting Communities: for COVID-19
The Connecting Communities newsletters include interesting news on public policies, healthcare innovations, isolation tips and more.
13 July 2020
We are going through unprecedented times that require unprecedented measures. The world is fighting the Covid-19 pandemic which it is having its repercussions on the way the international scientific community is organizing its meetings as well. Lockdowns and travel restrictions have required the cancellation of several global congresses. As a leading public health event, we cannot risk spreading the Covid-19 virus further by physically bringing thousands of people together in Rome in October. It is in this light that the Congress Management Committee (CMC) has decided to move the 16th World Congress on Public Health (WCPH 2020) into a virtual congress to be held 12 – 16 October 2020. Since we announced that the WCPH 2020 will be held as an entirely virtual and online congress we have worked hard on revising the programme of plenary and parallel sessions, networking opportunities and exhibition areas.
The virtual WCPH 2020 will be an exciting and engaging event with live streams of eight plenary sessions, 30 World Leadership Dialogues and 150 workshops. We will bring all accepted oral papers in pre-recorded sessions to life on our virtual platform with options for attendees to interact through chat boxes. Posters are clustered in congress tracks and viewable at all times. WCPH 2020 will offer an incredibly full and varied programme from 7:00 am to 9:00 pm CET to accommodate attendees living in different time zones across the globe.
When the WCPH actually takes place in October it is more relevant than ever. As the world confronts the coronavirus, the sharing of knowledge becomes ever more important, and the WCPH is the place to do it. A dedicated Covid-19 track will be featured, covering the latest on corona control policies, the efficacy of control measures, the impact on health systems and community services and the lessons to be learned from it.
Click for the Covid-19 programme here.
12 June 2020
On behalf of its members and partnering institutions, and based on four focus groups and a two-part survey, the EFPC has prepared a statement on Covid-19.
"It is our intention that this statement highlights the impacts that the current COVID-19 pandemic will have on two vulnerable groups: within the field of mental health and within elderly populations. Furthermore, we wish to highlight the collateral damage as a result of health systems operating within ‘COVID-19 Mode’."
Based upon this statement, the EFPC has also created several messages for health policy which can be used as a rough guide when implementing and/or creating policy.
10 June 2020
The Health System Response Monitor (HSRM) is an evolving collection of evidence on health systems' responses to COVID-19
European Observatory on Health Systems and Policies.
9 June 2020
Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
Derek K Chu, Elie A Akl, Stephanie Duda, Karla Solo, Sally Yaacoub, Holger J Schünemann on behalf of the COVID-19 Systematic Urgent Review Group Effort (SURGE) study authors
Physical distancing, face masks, and eye protection for prevention of COVID-19
C Raina MacIntyre, Quanyi Wang
Informal home care providers: the forgotten health-care workers during the COVID-19 pandemic
Emily Ying Yang Chan, Nina Gobat, Jean H Kim, Elizabeth A Newnham, Zhe Huang, Heidi Hung, Caroline Dubois, Kevin Kei Ching Hung, Eliza Lai Yi Wong, Samuel Yeung Shan Wong
Active case finding with case management: the key to tackling the COVID-19 pandemic
Zhongjie Li, Qiulan Chen, Luzhao Feng, Lance Rodewald, Yinyin Xia, Hailiang Yu, Ruochen Zhang, Zhijie An, Wenwu Yin, Wei Chen, Ying Qin, Zhibin Peng, Ting Zhang, Daxin Ni, Jinzhao Cui, Qing Wang, Xiaokun Yang, Muli Zhang, Xiang Ren, Dan Wu, Xiaojin Sun, Yuanqiu Li, Lei Zhou, Xiaopeng Qi, Tie Song, George F Gao, Zijian Feng and the China CDC COVID-19 Emergency Response Strategy Team The Lancet
Quantifying additional COVID-19 symptoms will save lives
Cristina Menni, Carole H Sudre, Claire J Steves, Sebastien Ourselin, Tim D Spector
Early evidence of pronounced brain involvement in fatal COVID-19 outcomes
Claus Hann von Weyhern, Ines Kaufmann, Frauke Neff, Marcus Kremer
The WHO we want
Olivier Nay, Marie-Paule Kieny, Lelio Marmora, Michel Kazatchkine
Department of Error
Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Mandeep R Mehra, Frank Ruschitzka, Amit N Patel
5 June 2020
Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study
Eloi Marijon, Nicole Karam, Daniel Jost, David Perrot, Benoit Frattini, Clément Derkenne, Ardalan Sharifzadehgan, Victor Waldmann, Frankie Beganton, Kumar Narayanan, Antoine Lafont, Wulfran Bougouin, Xavier Jouven
The Lancet Public Health
Rethinking the role of the school after COVID-19
Annamaria Colao, Prisco Piscitelli, Manuela Pulimeno, Salvatore Colazzo, Alessandro Miani, Stefania Giannini
The Lancet Public Health
COVID-19: long-term effects on the community response to cardiac arrest?
Gavin D Perkins, Keith Couper
The Lancet Public Health
4 June 2020
This series of situational and policy briefs summarises key practical and operational aspects of the COVID-19 response in relation to migrants and refugees. They include public health and policy recommendations and perspectives that build on the Lancet Migration Global Statement recommendations to ensure migrants and refugees: have access to healthcare; are included in prevention, preparedness and response; and are part of responsible and transparent public information strategies, during the COVID-19 pandemic. They are intended to be short briefs providing key information on particular migrant and refugee contexts and thematics, rather than fully comprehensive country or regional overviews.
20 May 2020
For several months now, the world has been gripped by the COVID-19 pandemic. It is obvious that international collaboration is key to combatting a global outbreak of this magnitude. Coordination and concerted action are needed, as well as the exchange of surveillance data and research outcomes. As the specialized United Nations agency for health, the World Health Organization (WHO) has a pivotal role in this, facilitating interaction and collaboration between all the member states, continuously monitoring the evolution of the pandemic, and developing guidance for member states to put in place appropriate measures. Read the full statement here.
19 May 2020
As COVID-19 poses an unprecedented challenge to all of us, it is vital that the measures adopted are human rights compliant and people-centered. The United Nations Human Rights Office (OHCHR) has created a dedicated webpage with human rights resources to inform and assist policy-makers with the COVID-19 response. New guidance and materials are uploaded on a daily basis.
12 May 2020
EUPHA and EPHA joint statement: Digitalisation to support an effective public health response to the COVID-19 emergency
The COVID-19 crisis is demonstrating the potential of digital health technology to manage some of our greatest public health challenges. In COVID-19 times, communicating the purpose, objectives and direction of digitalisation in public health is increasingly important as data-driven solutions become more common, presenting new ethical challenges. The access and affordability, inclusion, diversity and transparency, the intended and unintended effects around these new technological developments must also be critically addressed. To fully leverage digital innovation in public health, EPHA and EUPHA aim to create a
suitable environment for the introduction of emerging digital technologies, including by better informing policymakers about real societal needs and by training public health professionals, patients and other end users so they can effectively engage with digital tools in practice, policy and research.
Read the full statement here.
The COVID-19 Health System Response Monitor, a joint undertaking between the WHO Regional Office for Europe, the European Commission and the European Observatory on Health Systems and Policies, is a new online platform to provide countries and stakeholders in the WHO European Region with evidence of how national health systems are responding to the COVID-19 pandemic. The website systematically maps and analyses health system responses to the pandemic across the Region. Thus, it offers cross-country comparisons for analyses of the measures being taken by national authorities and also tracks wider public health initiatives.
A cross-country analysis can be found here.
7 May 2020
Softening the blow of the pandemic: will the International Monetary Fund and World Bank make things worse?
This article was published in The Lancet Global News on 9 April. Click on the title to access the article.
22 April 2020
Statement EUPHA on Combatting COVID-19: the importance of sharing knowledge to create a comprehensive and publicly available evidence-base
The COVID-19 outbreak is affecting everyone worldwide, and policymakers, scientists and practitioners are exploring uncharted territory while trying to get to grips with this new virus. Especially in such times of great uncertainty, building on up-to-date and accurate information is crucial. Therefore, EUPHA released a statement on the importance of sharing data, research outcomes and experiences to build a common, growing body of intelligence. A comprehensive and publicly available evidence-base is key when battling the outbreak and saving lives.
24 March 2020
Reducing the impact of the coronavirus crisis on those ‘left behind’ – Disadvantaged Migrants and Ethnic Minorities (MEM).
The Migrant and Ethnic Minority Health section of EUPHA comprises of more than 1800 practitioners, scholars and researchers across Europe and beyond (81 countries). This statement and call for action has been prepared by the EUPHA MEM Section Steering Committee and others on behalf of the membership.
The Statement was kindly translated in Spanish and can be found here.
4 March 2020
ASPHER provides a COVID-19 Resource Page, which includes information, communications and best practices from Schools of Public Health - both in English and local languages. https://www.aspher.org/covid-19-coronavirus-response.html
26 February 2020
In February 2018, the World Health Organization (WHO) placed Disease X on the list of priority diseases in its research and development blueprint for action to prevent epidemics. According to the WHO, Disease X represents “the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease”. Exactly two years later, public health agencies and their partners around the world are preparing against and responding to the coronavirus disease (COVID-19) outbreak, caused by a previously unknown virus which was first detected in China in December 2019. As of February 25th 2020, the virus has already infected at least 80,239 individuals of which at least 279 (including 7 deaths) in Europe. As the umbrella organisation for public health associations in the European region, EUPHA stands with its members and colleagues in each country who are working tirelessly to detect and manage cases, identify contacts and prepare health services for worst-case scenarios. At a time where sustained transmission in places outside of China, including in some European countries, is looking increasingly likely, preparedness and surveillance remain critical. EUPHA is particularly watching the evolving situation in Italy, recognising that similar situations are likely to occur in other countries in the region.
Our understanding of the virus and its spread is changing every day, and critical information that impacts on how the outbreak can be managed is emerging every day. As such it remains essential that public health professionals and others involved in the management of the outbreak keep themselves up to date with the latest evidence to ensure evidence-based actions of maximum effectiveness. At the same time, the volume of information available can be overwhelming and misinformation, deliberate or not, can cause confusion. It is important therefore to obtain information from trustworthy sources. Regional and global public agencies, as well as scientific publishers have made key publications, data and guidelines freely available through regularly update portal and EUPHA recommends its members to regularly look for updates through the following sources:
For the latest global data, evidence and guidance:
For EU specific guidance, surveillance updates and risk assessments:
In addition, many scientific publishers are expediting the publication of COVID-19 related evidence and making it available free of charge. Examples include:
- The New England Journal of Medicine – https://www.nejm.org/coronavirus
- The Lancet – https://www.thelancet.com/coronavirus
- Eurosurveillance – https://www.eurosurveillance.org/content/2019-ncov
- Cambridge University Press – https://www.cambridge.org/core/news/free-access-to-coronavirus-research
- Elsevier – https://www.elsevier.com/connect/coronavirus-information-center
- Springer – https://www.springernature.com/gp/researchers/campaigns/coronavirus
You can also follow the outbreak and receive key new information through the EUPHA Infectious Diseases Control section Twitter account: @euphaidc.
EUPHA stands with its members through these challenging times and will continue to actively monitor the situation in order to offer the most appropriate support it can to all those currently involved in fighting this threat.